Point of Care (PoC) Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Product; By Platform (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays); By End-Use; By Region; Segment Forecast, 2023 - 2032

Point of Care (PoC) Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Product; By Platform (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays); By End-Use; By Region; Segment Forecast, 2023 - 2032

The global point of care (PoC) diagnostics market size is expected to reach USD 115.44 billion by 2032, according to a new study by Polaris Market Research. The report “Point of Care (PoC) Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Product; By Platform (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays); By End-Use; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of the Point-of-Care (POC) diagnostics industry attributed by, there has been a significant increase in the prevalence of infectious diseases over the past decade. This rise has created a higher demand for rapid and accurate diagnostic tests that can be performed at the point of care, enabling immediate treatment decisions and reducing the spread of these diseases.

Technological advancements have also played a crucial role in the growth of the POC diagnostics industry. With the development of innovative and user-friendly devices, patients can now receive healthcare services at home. This is particularly important for the geriatric population, who may struggle to access traditional healthcare settings. POC diagnostics enable convenient and timely healthcare delivery, improving patient outcomes and reducing the burden on healthcare systems.

The market is experiencing notable trends and developments due to the growing adoption of rapid diagnostic tests (RDTs) and their quick and on-site results, which are particularly valuable in emergency and remote healthcare settings. Technological advancements, such as miniaturization and smartphone integration, have improved the performance and accessibility of point-of-care devices. Additionally, there is an increased focus on infectious disease testing, with point-of-care tests being crucial in rapidly identifying pathogens like COVID-19, malaria, and influenza.

In addition, the shift towards personalized medicine is leveraging point-of-care diagnostics. Real-time patient data and immediate test results enable healthcare professionals to make tailored treatment decisions based on individual needs, optimizing patient care. Chronic disease management, including diabetes and cardiovascular diseases, also benefits from point-of-care diagnostics, allowing for regular biomarker monitoring and timely intervention. Moreover, the market is expanding into home healthcare, where patients can perform certain tests themselves, empowering them and facilitating remote monitoring.

Point of Care (PoC) Diagnostics Market Report Highlights

The glucose testing segment accounted for the largest share of the market due to the increasing prevalence of diabetes and related conditions.

The clinics segment dominated the market with the highest revenue shares due to the increasing development of PoC diagnostics laboratory centers within clinics.

North American region holds the largest revenue shares of the market in 2022 due to there is the presence of well-established key players in this region and their contribution to market expansion. Also, government sponsors various research bodies.

The global key market players include Siemens Healthineers, Roche Diagnostics, Chembio Diagnostic Systems, Johnson & Johnson, Abbott Laboratories, Becton, Dickinson and Company, Instrumentation Laboratory Company, and others.

Polaris Market Research has segmented the Point of Care (PoC) Diagnostics market report based on product, platform, end-use, and region:

Point of Care (PoC) Diagnostics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

Glucose Testing

Hb1Ac Testing

Coagulation

Fertility

Infectious Diseases

HIV

Clostridium Difficile

HBV

Pneumonia or Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV)

HPV

Influenza/Flu

HCV

MRSA

TB and Drug-Resistant TB

HSV

Others

Cardiac Markers

Thyroid Stimulating Hormone

Hematology

Primary Care Systems

Decentralized Clinical Chemistry

Feces

Lipid Testing

Cancer Marker

Blood Gas/Electrolytes

Ambulatory Chemistry

Drug Abuse Testing

Urinalysis

Point of Care (PoC) Diagnostics, Platform Outlook (Revenue - USD Billion, 2019 - 2032)

Lateral Flow Assays

Dipsticks

Microfluidics

Molecular Diagnostics

Immunoassays

Point of Care (PoC) Diagnostics, End-use Outlook (Revenue - USD Billion, 2019 - 2032)

Clinics

Physician Office

Pharmacy & Retail Clinics

Non-practice Clinics

Urgent Care Clinic

Hospitals

Home

Assisted Living Healthcare Facilities

Laboratory

Point of Care (PoC) Diagnostics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa